文献速递血液净化与透析肾血管病与高血压

生物电阻抗指导的容量管理及维生素D补充对腹膜透析患者左心室质量的影响:一项随机对照试验

Impact of Bioelectrical Impedance-Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial.
PubMed 文献 · Am J Kidney Dis · 2021-10-14

主要结局为1年时心脏磁共振测得的LV mass变化。结果显示BIA组总体水(TBW)较常规护理组显著下降,但LV mass变化无组间差异;维生素D补充显著提高血清25-羟基维生素D浓度,但对LV mass无影响。

要点

  • BIA指导的容量管理可适度降低总体水,但未显著改变左心室质量。
  • 每周口服胆钙化醇可显著提升血清25-羟基维生素D水平,但对左心室质量无影响。
  • 在腹膜透析患者中,容量管理或维生素D补充对左心室肥厚的改善作用有限。

核心结论

  • BIA指导的容量管理对容量状态有适度影响,但对左心室质量变化无影响。
  • 维生素D补充可提高血清维生素D浓度,但对左心室质量无影响。

研究设计与样本

  • 干预包括BIA指导的容量管理对比常规护理,以及口服胆钙化醇对比安慰剂。
  • 主要结局为1年时心脏磁共振测得的左心室质量变化。

主要发现

  • BIA组总体水下降0.9±2.4 L,常规护理组增加1.5±3.4 L,校正组间差异为-2.4 L(95% CI, -4.1至-0.68),P=0.01。
  • BIA组左心室质量增加1.3±14.3 g,常规护理组减少2.4±37.7 g,组间差异+2.2 g(95% CI, -13.9至18.3),P=0.8。
  • 胆钙化醇组血清25-羟基维生素D浓度平均增加17.2±30.8 nmol/L,安慰剂组下降8.2±24.3 nmol/L,组间差异28.3 nmol/L(95% CI, 17.2至39.4),P<0.001。
  • 胆钙化醇组左心室质量减少3.0±28.1 g,安慰剂组增加2.0±31.2 g,组间差异-4.5 g(95% CI, -20.4至11.5),P=0.6。

临床怎么用

  • 对于腹膜透析患者,BIA指导的容量管理可考虑用于优化容量状态,但不应期望其显著改善左心室质量。
  • 维生素D补充可用于纠正缺乏,但不足以作为减少左心室肥厚的特异性干预。

局限性

  • 样本量相对较小,且左心室质量变化变异大于预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Hypervolemia and vitamin D deficiency occur frequently in patients receiving peritoneal dialysis and may contribute to left ventricular (LV) hypertrophy. The effect of bioelectrical impedance analysis (BIA)-guided volume management or vitamin D supplementation on LV mass among those receiving peritoneal dialysis is uncertain. STUDY DESIGN: Two-by-two factorial randomized controlled trial. SETTING & PARTICIPANTS: Sixty-five patients receiving maintenance peritoneal dialysis. INTERVENTION: BIA-guided volume management versus usual care and oral cholecalciferol 50,000 U weekly for 8 weeks followed by 10,000 U weekly for 44 weeks or matching placebo. OUTCOME: Change in LV mass at 1 year measured by cardiac magnetic resonance imaging. RESULTS: Total body water decreased by 0.9 + 2.4 (SD) L in the BIA group compared with a 1.5 ± 3.4 L increase in the usual care group (adjusted between-group difference: -2.4 [95% CI, -4.1 to -0.68] L, P = 0.01). LV mass increased by 1.3 ± 14.3 g in the BIA group and decreased by 2.4 ± 37.7 g in the usual care group (between-group difference: +2.2 [95% CI, -13.9 to 18.3] g, P = 0.8). Serum 25-hydroxyvitamin D concentration increased by a mean of 17.2 ± 30.8 nmol/L in the cholecalciferol group and declined by 8.2 ± 24.3 nmol/L in the placebo group (between-group difference: 28.3 [95% CI, 17.2-39.4] nmol/L, P < 0.001). LV mass decreased by 3.0 ± 28.1 g in the cholecalciferol group and increased by 2.0 ± 31.2 g in the placebo group (between-group difference: -4.5 [95% CI, -20.4 to 11.5] g, P = 0.6). LIMITATIONS: Relatively small sample size with larger than expected variation in change in LV mass. CONCLUSIONS: BIA-guided volume management had a modest impact on volume status with no effect on the change in LV mass. Vitamin D supplementation increased serum vitamin D concentration but had no effect on LV mass. FUNDING: Unrestricted Baxter International extramural grant and the Kidney Foundation of Canada. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01045980.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Brimble KS, Ganame J, Margetts P, et al. Impact of Bioelectrical Impedance-Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. Am J Kidney Dis. 2021. PMID: 34656640. doi:10.1053/j.ajkd.2021.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。